DrugBiological
Ivuxolimab clinical trials
Also written PF-04518600.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 3 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 4
M.D. Anderson Cancer Center (2) · University of Southern California (1) · Pfizer (1) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Utomilumab (2) · Avelumab (1) · Azacitidine (1) · Gemtuzumab (1) · Glasdegib (1) · Venetoclax (1) · Rituximab (1)
Studies
Open first, then newest update. How each study uses ivuxolimab is read from its arms, and is right about nine times in ten.
Testing it · 5
- Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced MalignanciesActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT03217747Written as Ivuxolimab
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney CancerActive, not recruitingPhase 2University of Southern CaliforniaNCT03092856Written as Anti-OX40 Antibody PF-04518600
- Rituximab + Immunotherapy in Follicular LymphomaTerminatedPhase 1Dana-Farber Cancer InstituteNCT03636503Written as PF04518600
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03390296Written as Anti-OX40 Agonist Monoclonal Antibody PF-04518600
- Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566CompletedPhase 1PfizerNCT02315066Written as PF-04518600
Given in every arm · 3 — ivuxolimab is usual care beside what is tested
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingActive, not recruitingPhase 3PfizerNCT05059522Written as PF04518600
- Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerActive, not recruitingPhase 2Laura Huppert, MD, BANCT03971409Written as Anti-OX40 Antibody PF-04518600
- A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedPhase 1/2PfizerNCT02554812Written as PF-04518600
Codes
What other systems call ivuxolimab · ClinicalTrials.gg INT002116
- MeSH (NLM) C000731456ivuxolimabOne source NLM
- UNII (FDA) APS3IS9D6WIVUXOLIMABConfirmed FDA, NLM
- NCI Thesaurus C121927IvuxolimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731456 | ivuxolimab | One source NLM |
| UNII (FDA) | APS3IS9D6W | IVUXOLIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C121927 | Ivuxolimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.